These guidelines are a consensus document developed by a working party of the Australian and New Zealand Anaesthetic Allergy Group (ANZAAG) to provide an approach to the investigation of perioperative anaphylaxis. They focus primarily on the use of skin testing as it is the investigation with the greatest clinical utility for the identification of the likely causative agent and potentially safer alternatives. The practicalities and process of skin testing, its limitations, and the place of other tests are discussed. These guidelines also address the roles of graded challenge and in vitro testing. The implications of anaphylaxis associated with neuromuscular blocking agents, beta-lactam antibiotics, local anaesthetic agents and chlorhexidine are discussed. Evidence for the recommendations is derived from literature searches using the words skin test, allergy, anaphylaxis, anaesthesia, and each of the individual agents listed in these guidelines. The individual articles were then reviewed for suitability for inclusion in these guidelines. Where evidence was not strong, as is the situation for many perioperative agents, expert consensus from the ANZAAG working party was used. These guidelines are intended for use by specialists involved in the investigation of perioperative allergy. They have been approved following peer review by members of ANZAAG and are available on the ANZAAG website: http://www.anzaag.com/anaphylaxis-management/testing-guidelines.pdf.
Perioperative anaphylaxis is associated with significant morbidity and mortality. The Australian and New Zealand Anaesthetic Allergy Group (ANZAAG) identified the need for a consistent and evidence-based approach to the investigation of patients who have had perioperative anaphylaxis to ensure their safe future management and have published these guidelines to promote this approach.
These guidelines are intended for use by specialists involved in the investigation of perioperative allergy. They have been approved following peer review by members of ANZAAG.
These guidelines are based on the best available evidence, which for many of the perioperative agents is based predominantly on expert opinion and requires validation. The use of a standardised approach to testing will facilitate the collection of comparable data from multiple centres enabling validation of the investigative process.
This document will be reviewed on a three-year cycle and updated accordingly. Correspondence regarding this document should be directed through to ANZAAG via email at admin@anzaag.com.
Definition of anaphylaxis
Anaphylaxis is "a severe, potentially fatal, systemic allergic reaction that occurs suddenly after contact with an allergycausing substance" 1 .
General considerations
Skin prick testing (SPT) and intradermal testing (IDT) are the primary tools used for the identification of immediate hypersensitivity reactions. They are both designed to trigger localised mast cell degranulation that is manifest by a wheal and flare response. SPT is most frequently used for investigation of food and aeroallergen allergy. It is not useful for delayed type hypersensitivity testing. IDT is useful for delayed type hypersensitivity testing due to the ability to perform a delayed read 2 .
International guidelines for perioperative allergy testing are available, which outline performance of SPT initially with a process of escalation to maximal IDT concentrations 3, 4 . Fisher described the use of IDT without preceding SPT to identify the causative agent in anaphylaxis to anaesthetic agents in 1981 5 . Since this time, IDT has been the most common technique used to investigate perioperative allergy in Australasian centres. Reasons for this approach have included the greater sensitivity of IDT compared with SPT 3, 4, 6 and the poor negative predictive value of SPT for drug hypersensitivity testing compared with IDT. The use of IDT at the outset aims to minimise the occurrence of false negative skin test results and provide optimal guidance for subsequent choice of anaesthetic agents. If SPT is performed and is negative, then the practitioner should always consider performing IDT.
Skin testing by the inexperienced practitioner
Skin testing was developed as a tool to determine the drug or drugs responsible after an episode of suspected perioperative anaphylaxis. It is only in this context that the specificity and sensitivity of IDT has been determined, whilst the positive and negative predictive values are influenced by the history and other tests including serum tryptase and specific IgE. Skin testing was not developed as a screening tool.
The process of testing, an understanding of the factors that might affect the result, the use and significance of positive and negative controls and the interpretation of the history and results requires some degree of experience and knowledge in order for safe recommendations to be made about the future use of drugs.
ANZAAG members may be asked by anaesthetists unfamiliar with skin testing to advise on the use of skin testing in the immediate preoperative period to screen a patient for allergy to perioperative agents. For the safety of patients, ANZAAG does not recommend occasional testing by inexperienced users.
Indications for skin testing
It is recommended that skin testing be performed in all cases with a strong clinical history supporting the diagnosis of perioperative anaphylaxis 7, 8 . Skin testing may also be considered in individuals with a less severe immediate hypersensitivity reaction.
Where there is an acute elevation in serum tryptase contemporaneous with an anaphylactic reaction skin testing is recommended. If the clinical picture is strongly suggestive of anaphylaxis skin testing is recommended even in the absence of an elevated tryptase 9 .
It is recommended that patients be referred for assessment and testing prior to surgery where there is suspicion of a previously uninvestigated perioperative anaphylactic reaction 10 . This may only be practical when the surgery is elective.
Skin testing is not validated as a screening tool and should not be performed in the absence of a personal history of perioperative anaphylaxis 11 .
Contraindications and precautions
Conditions which contraindicate or preclude skin testing 
Drugs which may interfere with skin testing results
There are several classes of drugs that might reduce skin reactivity and the cessation of these drugs should be considered prior to testing. These drugs include H1 receptor blockers (antihistamines), H2 receptor blockers, corticosteroids, antidepressants and antipsychotics with antihistamine activity.
H1 receptor blockers (antihistamines)
There is clear evidence that H1 receptor antagonists interfere with skin responsiveness and, in most patients, these drugs can be stopped prior to skin testing. First generation antihistamines generally have a short duration of action, but newer antihistamines have a much longer halflife. It is recommended that the ASCIA (Australasian Society of Clinical Immunology and Allergy) guidelines 2 for cessation of antihistamines are followed (see Appendix 1) . In general, cessation of antihistamines one week prior to testing is adequate.
It should be noted that many over-the-counter cough and cold remedies, nasal sprays and eye drops contain antihistamines.
H2 receptor blockers
Ranitidine, famotidine and cimetidine have limited effect on skin reactivity, but this effect might be enhanced with co-administration of H1 antihistamines. Cessation on the day of testing is probably adequate 13 .
Antidepressants and antipsychotics with antihistamine activity
Many tricyclic antidepressants including doxepin, imipramine and amitriptyline, and some tetracyclics including mirtazapine and mianserin have a variable antihistamine effect. Antipsychotics (also called neuroleptics and psychotropics) including olanzapine and quetiapine also have antihistamine effects.
Whilst they might interfere with skin reactivity, abrupt unsupervised cessation is inadvisable. This must be taken into account in the interpretation of the results if they are not ceased prior to testing.
Topical corticosteroids
The application of topical corticosteroids at the site of testing does have an effect on skin reactivity. They should be ceased one week prior to testing 14 .
Drugs that have no effect on skin testing interpretation

Montelukast
Montelukast is a leukotriene receptor antagonist used in the management of asthma. It blocks the action of the inflammatory mediator leukotriene, and therefore might be expected to impair the response to skin testing.
However, there is little evidence that montelukast interferes with the interpretation of skin tests 15, 16 and therefore cessation is not required.
Oral and inhaled corticosteroids
Short and long term systemic corticosteroids do not need to be stopped prior to testing 17 . There is little evidence regarding the effect of inhaled corticosteroids, but as their systemic absorption is limited, there should be little effect on skin testing 13 .
Drugs which may increase the morbidity of skin testing
Beta-blockers and angiotensin converting enzyme inhibitors
The rationale for recommending cessation of these drugs is related to the theoretical concern that a severe reaction occurring during testing may be more difficult to treat due to the pharmacological effects of these drugs.
Abrupt cessation of these drugs may predispose to morbidity. The risk of a systemic reaction to intradermal testing is low. On the balance of risk, it is recommended that these drugs be continued.
Minimum facilities required for the performance of skin testing
A number of guidelines outline the steps required for the management of anaphylaxis [18] [19] [20] . Although systemic reactions in association with skin testing are rare 21 , centres conducting testing must be skilled and equipped to rapidly administer initial treatment measures in the event of anaphylaxis. In accordance with these guidelines, the ability to administer adrenaline intramuscularly is essential. Testing facilities must also be able to deliver intravenous fluids, supplemental oxygen and have sufficient facilities and trained staff to perform cardiopulmonary resuscitation and assist ventilation if required.
Obtaining consent for skin testing ANZAAG recommends the following topics are discussed when obtaining informed consent from a patient prior to skin testing: • a description of the test • the risks of the test • the risks of not having the test • an explanation of false positive and false negative results and their implications • discussion with regards to the medications that can interfere with the results The patient should have an opportunity to ask questions before giving consent.
Additional consent should be sought for: • the acquisition and retention of a photographic or video record • the use of data/information for publication and/or teaching
Procedure
Timing of skin testing
Skin testing is ideally delayed for four to six weeks following a suspected anaphylactic reaction 3, 6, 22 . Under certain circumstances testing may need to performed prior to this time. If testing is performed prior to four to six weeks, only positive skin tests can be taken into account 3, 22 . There is little published data to provide guidance on early skin testing. The significance of a negative skin test performed prior to four to six weeks, including results of cross sensitivity amongst neuromuscular blocking agents (NMBAs), needs to be interpreted with caution 22, 23 . If testing is performed prior to four to six weeks, repeat testing after four to six weeks may be considered 3 .
Preparation of dilutions
Skin testing commonly requires the preparation of multiple dilutions of perioperative agents to ensure the patient is tested to the range of likely allergens to which they were exposed. Ideally, resources would allow that the testing dilutions be prepared, drawn up and labelled in a sterile environment in the pharmacy, with expiry dates for the injections applied accordingly. However, in the majority of centres there is no provision for this method of preparation, therefore the testing dilutions must be drawn up by the practitioner.
Preparation of drug dilutions by the practitioner performing the testing requires that all dilutions must be prepared, labelled and dispensed prior to patient attendance to ensure that multiple dosing cannot occur. All required injections should be drawn up, labelled and capped ready for individual patient use. The testing work surface should be separate from the one on which the dilution bags are stored. Only the drugs for the patient being tested should be on the testing work surface.
Drug stability in solution and the risk of bacterial colonisation must be taken into account. Most anaesthetic drugs, including midazolam, opiates and muscle relaxants are suitable for use for up to 24 hours after dilution if stored at less than 25 o C. However, it is recommended that propofol be used within six hours of dispensing 24 . Amoxycillin mixed with normal saline is reported to be suitable for use for up to eight hours 24 . On this basis, it is recommended that all drug dilutions used for skin testing are mixed and delivered within six hours.
Site of skin testing
The forearm and the back are both appropriate testing sites, with the skin on the back demonstrating slightly larger SPT reaction to allergen, but not histamine 25 . When using the forearm, testing should be performed at least 5 cm from the wrist and 3 cm from the antecubital fossa 26 .
Skin prick testing
Devices Some devices are designed to prick through a drop of allergen on the skin and some pick up a drop from a bottle and deliver the allergen as the device is pricked through the skin. The former are recommended as more appropriate for drug allergy testing.
Devices can either be designed for one allergen at a time and single use, e.g. Stallergenes prick lancet and ALK Spain SPT lancets, or multiple allergens at a time and single use. Single allergen metal lancets produce the most reproducible results, are best tolerated and may be the easiest to use, especially in relatively inexperienced hands 27, 28 .
Intravenous needles have been reviewed and whilst results are reasonably reproducible and sensitive, there is a higher risk of bleeding and excessive depth of penetration.
Scratch testing is not recommended as it is difficult to standardise the amount of allergen delivered and it requires excessive trauma to perform, increasing the risk of nonspecific results. There is also a higher risk of a systemic allergic response. 3. Apply enough pressure to the skin to cause a depression of 2 to 3 mm in the skin and hold for one second. 4. Position each test at least 2 cm apart to reduce interference from adjacent positive tests. Bleeding should not occur. Each lancet should be used only once.
Some practitioners will prick as each drop is placed on the skin prior to applying the next allergen, some will apply all the solutions and then prick. Either approach is acceptable, however pricking each allergen immediately after application may reduce the risk of spreading if the patient moves.
To reduce the risk of contamination allergen and control solutions should be blotted after one minute (e.g. with a tissue) rather than wiped off.
Intradermal testing
Devices IDT is typically performed using a 0.5 or 1.0 ml syringe with an attached 26 to 30 gauge hypodermic needle 26 . A 29 gauge needle is most commonly used by the authors.
Technique
The needle is directed at an angle of 5° to 10° to the surface of the skin 26, 29 . A volume of 0.02 to 0.05 ml of drug is injected intradermally 3, 4, 7, 26, 29, 30 , raising a small bleb measuring 3 to 4 mm in diameter 3, 7 . Caution must be taken to exclude any air bubbles prior to injection.
Position each test at least 2 cm apart to reduce interference from adjacent positive tests 26 .
Controls for skin testing
Negative controls are necessary as some people will display dermatographism and react to the physical trauma of skin testing rather than the allergen. This may produce a wheal of substantial size which makes results of skin tests to other substances uninterpretable 2, 6 . The negative control should be saline 6,7,12,31. Positive controls are necessary to demonstrate an appropriate response to histamine release by mast cells. There may be a reduced or absent response if the patient has taken antihistamines or drugs with antihistamine effects or if their skin is non-reactive 2,6 . The positive control should either be histamine 10 mg/ml by SPT or morphine 10 mcg/ml by IDT 2, 3, 6, 26, 32 .
Measurement of skin test responses
The histamine skin prick control should be read at 10 to 15 minutes 2 . All other results are read at 15 to 20 minutes [2] [3] [4] 7, 33 .
Whilst a positive response often involves a wheal and flare response, only the wheal requires measurement.
There is no single wheal measurement method that is used universally. Methods of wheal measurement include measurement of the longest diameter, the sum of the longest diameter and its orthogonal diameter divided by two (the mean), products of the diameters, planimetry, weighing of tracing paper or cellophane used to outline the wheal and computerised scanning.
ANZAAG consensus is to record the longest diameter of the wheal, its orthogonal (perpendicular) diameter and their mean in millimetres. The mean is the most commonly used measurement of wheal size. Whilst it may be intuitive that the area of the response would be the most appropriate measurement; planimetry, computerised scanning and the weighing of tracing paper or cellophane used to outline the wheal and are not commonly reported. They are technically difficult and/or time consuming.
Standardising wheal measurements will aid future analysis of data collected.
Skin prick test
The positive control must be at least 4mm in diameter 2 . The negative control must be less than 3 mm in diameter 2, 26 .
A result is positive if the wheal is at least 3 mm greater than the negative control 2, 3, 11, 12, 26 .
Intradermal test
A result is positive if the wheal doubles in size or increases by 3 mm 3, 4, 30, 34 .
If the reaction does not reach the above threshold, but it appears to be a more significant reaction than any of the other tested drugs, it may be reported as equivocal. It is possible that this is the causative agent. Consideration of the positive and negative controls should be taken into account when making this assessment.
The patient should remain under observation for 40 minutes after the commencement of any test 2 .
In vitro testing
Specific IgE testing
Testing of serum for specific IgE (sIgE) antibodies is available for a limited number of perioperative agents.
These tests can be useful, particularly when used in combination with the patient history and the results of skin testing but issues with sensitivity and specificity limit their value when used alone. The use of sIgE assays alone as a screening tool is not recommended. To identify which perioperative agent is likely to have caused an episode of anaphylaxis and which perioperative agent or agents may need to be avoided in the future, skin testing should be performed by an experienced perioperative allergy testing centre.
There are a number of sIgE tests that detect antibodies to the quaternary ammonium group found on NMBAs. They have a variety of names such as morphine, pholcodine, suxamethonium and rocuronium sIgEs. It is important to note that a positive morphine sIgE test is a marker of antibodies to the quaternary ammonium component of NMBAs and should not be interpreted to indicate hypersensitivity to morphine.
Basophil activation testing
Basophil activation tests have been reported in the literature to aid in the diagnosis of immediate type hypersensitivity to drugs. However, this technique is not freely available and is mostly applicable to research at this time. Further discussion of this test is beyond the scope of this document.
Testing of new perioperative agents
When a new agent is implicated as a possible cause of a perioperative allergic reaction, there is a need to determine the concentrations at which it should be skin tested. It is beyond the scope of these guidelines to make formal recommendations about the process for the determination of skin testing concentrations for new perioperative agents. New drugs and agents, such as antiseptics and IV fluids that cause perioperative allergic reactions, are constantly emerging and the question of testing concentrations needs to be addressed.
All perioperative agents have the potential to trigger both allergic and non-specific (non-allergic) reactions on skin testing. The non-irritating concentration (NIC) has been defined as the concentration at which an agent does not generally cause skin irritation in non-allergic individuals 35 . The NIC cannot be assumed to be the same for all agents, even of the same class. Certain agents (e.g. some NMBAs) are particularly prone to directly trigger mast cell degranulation and as a result the NIC for these agents is often lower than those of other drug classes. When skin testing is performed with more concentrated preparations than the NIC, a positive response is likely to be due to irritation and may not represent an allergic response. At concentrations equal to or below the NIC, a positive skin test is likely to represent a true positive skin test rather than non-specific skin irritation 4 .
There are published recommendations that explore processes by which the NIC can be determined for new drugs 4,35 that may serve as a guide for practitioners considering testing new agents and these will not be reviewed in detail in this document. The publication of attempts to determine the NIC for new perioperative agents is encouraged to add to the body of available information.
Graded challenge testing
At this time, the gold standard for demonstrating tolerance to an agent which has tested negative on skin testing is graded challenge. This procedure is intended to identify safe agents for use in subsequent anaesthesia, not to confirm causative agents, and should only be undertaken after negative skin testing. Whilst a comprehensive discussion of challenge testing is outside the scope of this document, there are good review articles on this topic which offer guidance to practitioners 36 . Due to the greater risk of reaction, it is recommended that challenge testing be undertaken only in centres experienced in both allergy management and investigation.
Anaphylaxis and specific agents
Neuromuscular blocking agents
NMBAs have been demonstrated to be the most common cause of perioperative anaphylaxis in Australasia 37, 38 .
Where an NMBA was administered perioperatively, testing must include the specific agent administered at the time of the reaction. Due to a very high degree of cross reactivity 30, 39 , it is important that skin testing is also conducted for a range of alternative NMBAs. This approach allows determination of the causative drug, identification of cross-reactive NMBAs (which must also be avoided) and those that are likely to be suitable for future use 3 .
When a clear culprit is identified, alternative skin test negative NMBAs are usually, but not invariably, safe 40, 41 . False negative results do occur and therefore all NMBAs must be used with caution during subsequent procedures. When a skin test negative alternative has been used safely in a subsequent anaesthetic, the patient's documentation should have this information added.
Betalactam antibiotics
An episode of perioperative anaphylaxis will often require the investigation of a betalactam antibiotic. This reflects the recommendation for the use of cephalosporins (particularly cephazolin) for antibiotic prophylaxis in many parts of the world including the New Zealand 42, 43 and Australian 44 antibiotic guidelines. Betalactam antibiotics have been identified as a common cause of perioperative anaphylaxis 30, 45, 46 . It is recommended that all antibiotics administered be investigated as part of testing after an episode of perioperative anaphylaxis 11 .
Multiple recent articles covering the complexity of investigating betalactam antibiotics are available 11, [47] [48] [49] [50] . A full review of this issue is beyond the scope of this document. However, given the frequency of betalactam use in the setting of perioperative anaphylaxis, some important general principles are summarised below.
The clinical history is critical in the diagnosis of betalactam hypersensitivity 48 . All testing and results must take into account the clinical context. Immediate hypersensitivity reactions to betalactams can be due to reactivity to the betalactam moiety or the side chain 47, 48 . Similarity of the side chains has been established to be an important determinant of cross reactivity between cephalosporins and penicillins 48, 49 .
Cross reactivity is not predictable on the basis of drug class or generation alone. Testing must include the same antibiotic that was used at the time of the reaction 11, 47 .
Skin testing remains the most important method for confirming betalactam allergy and clarifying cross-reactivity 47 . European consensus guidelines 47 for specialist centres testing for betalactam allergy and cross reactivity outline a step-wise approach. The initial step recommended is SPT including the major and minor penicillin determinants, amoxicillin and a range of cephalosporins. If negative, SPT is followed by IDT of this drug panel, with increasing concentrations to the NIC to increase sensitivity of the testing. However, there remains an important false negative rate with skin testing alone. Allergy to any of the betalactams can only be excluded after provocation testing with the specific drug that was administered at the time of the reaction. Positive oral provocation after negative skin test has been shown in some studies to occur in almost one-third of patients 11 .
It is not feasible or necessary to perform the formal protocol described above in all patients who have perioperative anaphylaxis in association with betalactam administration. A practical approach to these patients is to skin test the administered betalactam and the other agents administered prior to the onset of anaphylaxis. If SPT is used and fails to produce a positive result, then IDT must be performed.
Where there is negative IDT for the suspected antibiotic accompanied by a clear positive to another drug administered perioperatively (for example, a NMBA), it is reasonable to administer that antibiotic again in the future. A false negative cannot be excluded.
Where all agents administered perioperatively are skin test negative and there is a strong clinical story to support anaphylaxis, particularly in the presence of an elevated serum tryptase, the possibility of a false negative to the antibiotic agent must be considered. These patients may benefit from further antibiotic testing.
IDT is not valid for use as a screening test to predict immediate hypersensitivity to cephalosporins in the absence of a clinical history supporting prior anaphylaxis 51 .
Laboratory testing for sIgE is available for the penicillins and a limited number of cephalosporins. These tests have low sensitivity and their use is not routinely indicated.
Local anaesthetic agents
Whilst immediate hypersensitivity to amide local anaesthetic (LA) agents is rare 31, 52 , it is relatively common for patients to report adverse reactions following their administration. Consequently, it is important for practitioners to have an approach to testing for LA hypersensitivity. Skin testing is performed with the intention of identifying an agent that can be safely given to the patient. It is recommended that skin testing is undertaken with the suspect agent plus at least one alternative and is followed at least 30 minutes later by a subcutaneous challenge if skin testing is negative 31, 52, 53 .
In addition, it is important for practitioners to consider excipients or other agents present in commercially available LA preparations. These may be the cause of hypersensitivity reactions, in which case the LA alone may be well tolerated. It is important to avoid skin testing with preparations containing adrenaline or other vasoconstrictors due to the high likelihood of producing false negative results. In contrast to some reports 54 , the authors have not noted IDT for LA to be more uncomfortable than other agents, or associated with false positive results, even at neat concentrations.
As described above, an in-depth discussion of challenge testing is outside of the scope of this document. LA allergy is an issue that will frequently arise for anaesthetists and other practitioners undertaking perioperative allergy testing and is therefore covered briefly.
If skin testing is negative at maximal IDT concentration, a subcutaneous challenge should be considered. This may be undertaken using a graded protocol or a single step delivering 1 to 3 mls of undiluted LA subcutaneously 8, 52, 54, 55 . The latter approach is more commonly employed by the authors. In the event of a positive skin test, an alternative skin test negative LA should be challenged. Subcutaneous challenge carries a higher risk of anaphylaxis and must only be performed in a facility with resuscitation equipment and appropriately trained staff. As there is also the possibility of a delayed reaction when a subcutaneous challenge is performed, the patient should be followed up at 24 hours to assess for any delayed response.
Chlorhexidine
This widely used antiseptic is found in many wipes, gels, lubricants, dressing, drapes and devices in the perioperative environment and is increasing as a cause of anaphylaxis 56, 57 . The widespread and often undocumented use of this agent means that it is frequently unrecognised as a possible cause of allergic reactions 58, 59 . If the patient is exposed to chlorhexidine intravenously, such as with chlorhexidine impregnated central venous access devices, anaphylaxis is likely to develop rapidly 60 . If chlorhexidine is absorbed across mucous membranes anaphylaxis is often delayed, as may occur with chlorhexidine containing urethral gels. Information regarding chlorhexidine exposure is frequently incomplete at the time of patient referral 59 . Repeated episodes of chlorhexidine anaphylaxis have been reported to occur in some patients before chlorhexidine has been identified as the responsible allergen. In all cases of perioperative anaphylaxis, where it is not possible to be certain that there was no exposure to chlorhexidine, testing to chlorhexidine should be considered 58 .
Drug dilutions
Dilutions and drug concentrations reported in Table 1 (on next page) are drawn from published literature where possible, with references included. Where published data are lacking, reported dilutions and concentrations are based on the consensus opinion of report authors based on experience gained through multiple episodes of testing.
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